InMed recently reported results for FY19 and is on track for INM-755 for epidermolysis bullosa (EB) to be in the clinic by the end of 2019. The Phase I programme will consist of two trials, one in healthy volunteers with intact skin and the other in healthy volunteers with small wounds. A Phase I/II trial in EB patients is expected to begin in Q121. In glaucoma, the company has switched its lead candidate to INM-088, which has some specific advantages to the former lead, INM-085. Advanced pre
26 Sep 2019
InMed Pharmaceuticals - INM-755 getting closer to the clinic
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
InMed Pharmaceuticals - INM-755 getting closer to the clinic
- Published:
26 Sep 2019 -
Author:
Maxim Jacobs -
Pages:
5
InMed recently reported results for FY19 and is on track for INM-755 for epidermolysis bullosa (EB) to be in the clinic by the end of 2019. The Phase I programme will consist of two trials, one in healthy volunteers with intact skin and the other in healthy volunteers with small wounds. A Phase I/II trial in EB patients is expected to begin in Q121. In glaucoma, the company has switched its lead candidate to INM-088, which has some specific advantages to the former lead, INM-085. Advanced pre